Sanofi, Multiple Sclerosis
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug
TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection
MedPage Today16h
Women With MS Less Likely to Receive Treatment Than Men
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
FierceBiotech2d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Key biomarkers identified for predicting disability progression in multiple sclerosis
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Medpage Today on MSN3d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes
"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...
Medscape2d
High-Dose Vitamin D Linked to Lower Disease Activity in CIS
Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...
PHILADELPHIA.Today on MSN1d
Local Multiple Sclerosis Advocate Honored With State Citation
Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
California’s cap on health care costs is the nation’s strongest. But will patients notice?
Vickie Villegas had to pay $3,000 out-of-pocket every time she was treated for multiple sclerosis, a disease that attacks the ...
Medscape8d
Does Multiple Sclerosis Protect Against Alzheimer's?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
MedPage Today1d
Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...